Moderna reports third quarter 2022 financial results and provides business updates
Third quarter 2022 revenues of $3.4 billion; gaap net income of $1.0 billion and gaap diluted eps of $2.53 revenue from advance purchase agreements for anticipated delivery in 2022 expected to be $18 to $19 billion, following delay of certain deliveries into 2023 due to short-term supply constraints primary efficacy analysis from phase 2 study for personalized cancer vaccine program (mrna-4157/v940) expected in 4q22 phase 3 rsv vaccine efficacy data could read out this winter phase 3 flu vaccine immunogenicity data expected in 1q23 completed $3 billion share repurchase plan announced in february 2022; commenced august 2022 $3 billion share repurchase program cambridge, ma / accesswire / november 3, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today reported financial results and provided business updates for the third quarter of fiscal year 2022. "today's earnings continue to show strong corporate momentum.
MRNA Ratings Summary
MRNA Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission